Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma
Abstract While CD19-directed CAR T-cell therapy represents a transformative immunotherapy for relapsed/refractory large B-cell lymphoma (r/r LBCL), more than 50% of patients ultimately progress or relapse. Recently, the International Metabolic Prognostic Index (IMPI) – incorporating age, stage, and...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Nature Publishing Group
2025-08-01
|
| Rangatū: | Blood Cancer Journal |
| Urunga tuihono: | https://doi.org/10.1038/s41408-025-01338-1 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|
